Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93 CHF | -.--% | -.--% | -.--% |
05-15 | Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit | MT |
05-09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.18 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.44 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 181B | - | ||
+2.59% | 114B | C | ||
-2.75% | 68.29B | A | ||
+5.32% | 52.24B | B- | ||
+7.61% | 44.3B | B- | ||
+5.82% | 42.73B | B+ | ||
+25.17% | 32.52B | B | ||
+18.00% | 26.02B | A- | ||
-2.66% | 25.91B | A- | ||
-2.18% | 24.72B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABT Stock
- ABT Stock
- Ratings Abbott Laboratories